Clinical Trials
28 trialsNCT06051695 2026-05-26
EVEREST-2
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT05726864 2026-05-19
AMPLIFY-7P
Elicio Therapeutics
Phase 1/2 Active not recruiting
NCT06239194 2026-05-06
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
Phase 1/2 Recruiting
NCT06128551 2026-04-23
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1/2 Recruiting
NCT07213609 2026-03-23
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
GlaxoSmithKline
Phase 1/2 Recruiting
NCT06710847 2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT06682793 2025-09-09
DENALI-1
A2 Biotherapeutics Inc.
Phase 1/2 Recruiting
NCT06006390 2024-08-09
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Recruiting
NCT00788957 2024-08-07
Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
NantBioScience, Inc.
Phase 1/2 Completed
NCT01605318 2024-01-24
Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer
Gilead Sciences
Phase 1/2 Terminated
NCT03602079 2023-08-03
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase 1/2 Completed
NCT01347645 2023-06-22
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
Eisai Inc.
Phase 1/2 Terminated
NCT05538195 2022-09-13
Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Unknown
NCT02465593 2022-01-11
A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer
PharmaEngine
Phase 1/2 Terminated
NCT00040599 2021-08-19
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer
Gilead Sciences
Phase 1/2 Completed
NCT00041652 2021-08-19
Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
Gilead Sciences
Phase 1/2 Completed
NCT01394939 2021-01-08
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
SillaJen, Inc.
Phase 1/2 Completed
NCT01681472 2020-09-25
PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer
Isofol Medical AB
Phase 1/2 Completed
NCT01397305 2020-09-09
An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate (Arfolitixorin) and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer
Isofol Medical AB
Phase 1/2 Completed
NCT02973672 2019-07-18
Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas
Surgimab
Phase 1/2 Completed
NCT00816777 2018-09-07
PARAGON
Generic Devices Consulting, Inc.
Phase 1/2 Terminated
NCT03607643 2018-07-31
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Leaf Vertical Inc.
Phase 1/2 Unknown
NCT00149396 2018-04-24
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
MediGene
Phase 1/2 Completed
NCT01040000 2017-08-04
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
Precision Biologics, Inc
Phase 1/2 Completed
NCT00625651 2014-04-25
Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer
Amgen
Phase 1/2 Completed
NCT00630786 2014-02-06
Conatumumab/Panitumumab Combination Metastatic Colorectal Cancer Study
Amgen
Phase 1/2 Completed
NCT00403624 2010-08-27
Evaluation of the Neoadjuvant Treatment With Oxaliplatin -UFT- Radiotherapy in Rectal Cancer
Sanofi
Phase 1/2 Completed
NCT00259363 2009-12-07
Oxaliplatin in Rectal Cancer
Sanofi
Phase 1/2 Terminated